Citations

Clear

1011 citation(s) found for "Barry, WT".

Spinal Cord Temperature
Harrison, Barry, Shine, Timothy, Ruyter, Martin L. De, Murray, Michael J.

Mayo Clinic

Anesthesiology | December 24, 2003 | Volume: 100 | Issue: 1 | Pages: 198-199

10.1097/00000542-200401000-00046 | PMID 14695752 Get It

Neuropathy following Axillary Brachial Plexus Block: Is It the Tourniquet?
Jankowski, Christopher J., Keegan, Mark T. , Bolton, Charles F., Harrison, Barry

Mayo Clinic

Anesthesiology | November 10, 2003 | Volume: 99 | Issue: 5 | Pages: 1230-1232

10.1097/00000542-200311000-00036 | PMID 14576566 Get It

Osteogenesis Imperfecta, Perioperative Bleeding, and Desmopressin
Keegan, Mark T. , Whatcott, Brett D., Harrison, Barry

Mayo Clinic

Anesthesiology | November 10, 2003 | Volume: 97 | Issue: 4 | Pages: 1011-1013

10.1097/00000542-200210000-00039 | PMID 12357173 Get It

Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With β-Blockade in Patients With Heart Failure
Eichhorn, Eric J., Grayburn, Paul , Mayer, Susan A., Sutton, Martin St. John, Appleton, Christopher, Plehn, Jonathan F. , Oh, Jae K. , Greenberg, Barry , DeMaria, Anthony N. , Frantz, Robert P. , Krause‐Steinrauf, Heidi , Frantz, Robert P

Mayo Clinic

Circulation | November 4, 2003 | Volume: 108 | Issue: 19 | Pages: 2336-2341

10.1161/01.cir.0000097111.00170.7b | PMID 14597587 Get It

Background— β-Blockers improve survival and reduce hospitalization in chronic heart failure (CHF) by biologically improving left ventricular ejection fraction (LVEF). However, a good predictor of improvement with this therapy has not been identified. This substudy of BEST examined whether myocardial contractile reserve, as determined by dobutamine stress echocardiography, predicts improvement in LVEF. Methods and Results— Seventy-nine patients with class III/IV CHF underwent dobutamine stress echocardiography before treatment with bucindolol (n=41) or placebo (n=38). Regional wall motion score index (WMSI) was calculated as the sum of the scores in each segment divided by the total number of segments visualized. WMSI was compared with change in LVEF after 3 months of therapy as determined by gated radionuclide scan. Change in WMSI correlated inversely with change in LVEF after 3 months of bucindolol ( r =−0.72, P <0.0001) and was the most significant multivariate predictor of change in LVEF ( P =0.0002). Patients with contractile reserve had demographics similar to those of patients without contractile reserve, including RVEF, LVEF, systolic blood pressure, and CHF duration. However, patients without contractile reserve had higher baseline plasma norepinephrine levels (687±333 versus 420±246 pg/mL, P <0.05) and greater decrease in plasma norepinephrine in response to bucindolol (−249±171 versus −35±277 pg/mL, P <0.05). Conclusions— This study suggests a direct relationship between contractile reserve and improvement in LVEF with β-blocker therapy in patients with advanced CHF. Patients without contractile reserve have higher resting adrenergic drive, as reflected by plasma norepinephrine, and may experience greater sympatholytic effects from bucindolol.
A Genome-Wide Scan for Urinary Albumin Excretion in Hypertensive Families
Beck, Stephanie R., Rich, Stephen S. , Heiss, Gerardo , Lewis, Cora E. , Province, Michael A. , Schwander, Karen , Arnett, Donna K. , Mellen, Beverly G., Freedman, Barry I. , Turner, Stephen T. , Rich, Stephen S , Arnett, Donna K , Province, Mike

Mayo Clinic

Hypertension | August 19, 2003 | Volume: 42 | Issue: 3 | Pages: 291-296

10.1161/01.hyp.0000087890.33245.41 | PMID 12925555 Get It

Albuminuria increases the risk of cardiovascular events in patients with essential hypertension and diabetic subjects. The heritability (h 2 ) of albuminuria in multiplex hypertensive families is unknown. We calculated the familial aggregation of urine albumin:creatinine ratio (ACR) and performed a genome-wide scan to assess for loci contributing to ACR in participants enrolled in the Hyper tension G enetic E pidemiology N etwork (HyperGEN). To perform the genome scan, we analyzed genotype results from 2589 individuals from 805 families in the Family Blood Pressure Program. ACR and covariates were available in 1727 individuals (mean age, 57.1 years). Estimates of h 2 were obtained by using variance component methodology as implemented in the SOLAR software package. Linkage was tested between 387 markers spanning the genome at an average interval of 9.32 cM, using SOLAR multipoint analysis. The h 2 of log urine ACR was 0.49 ( P <1×10 −7 ) after controlling for significant main and interactive effects of age, gender, race, body mass index, blood pressure, and use of ACE inhibitors or angiotensin-2 receptor blockers. The genome-wide scan revealed a maximum LOD score of 2.73 on chromosome 19 (robust corrected LOD, 2.40; P =0.0009) at marker D19S591 and a LOD score of 2.0 on chromosome 12 (robust corrected LOD, 1.75; P =0.005) at marker PAH. These analyses demonstrate the marked heritability of urine ACR in families enriched for the presence of members with essential hypertension. They suggest that a gene(s) associated with urinary ACR may be present on human chromosomes 19 and 12.
Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia
Lama, Vibha N. , Flaherty, Kevin R. , Toews, Galen B., Colby, Thomas V. , Long, Qi , Murray, Susan , Kazerooni, Ella A. , Gross, Barry H., Lynch, Joseph P., Long, Qi , Travis, William D. , Martínez, Fernando J. , Long, Qi

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 18, 2003 | Volume: 168 | Issue: 9 | Pages: 1084-1090

10.1164/rccm.200302-219oc | PMID 12917227 Get It

Abstract Exercise-induced hypoxia is an index of the severity of interstitial lung disease. We hypothesized that desaturation during a 6-minute walk test would predict mortality for patients with usual interstitial pneumonia (n = 83) and nonspecific interstitial pneumonia (n = 22). Consecutive patients with biopsy-proven disease performed a 6-minute walk test between January 1996 and December 2001. Desaturation was defined as a fall in oxygen saturation to 88% or less during the 6-minute walk test. Desaturation was common (44 of 83 usual interstitial pneumonia and 8 of 22 nonspecific interstitial pneumonia; chi square, p = 0.39). Patients with usual interstitial pneumonia or nonspecific interstitial pneumonia who desaturated had a significantly higher mortality than patients who did not desaturate (respective log-rank tests, p = 0.0018, p = 0.0089). In patients with usual interstitial pneumonia, the presence of desaturation was associated with an increased hazard of death (hazard ratio, 4.2; 95% confidence interval, 1.40, 12.56; p = 0.01) after adjusting for age, sex, smoking, baseline diffusion capacity for carbon monoxide, FVC, and resting saturation. We conclude that knowledge of desaturation during a 6-minute walk test adds prognostic information for patients with usual interstitial pneumonia and nonspecific interstitial pneumonia.
Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , Mumford, Jeanette A. , Murray, Susan , Kazerooni, Ella A. , Gross, Barry H., Colby, Thomas V. , Flint, Andrew , Toews, Galen B., Lynch, Joseph P., Travis, William D. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 3, 2003 | Volume: 168 | Issue: 5 | Pages: 543-548

10.1164/rccm.200209-1112oc | PMID 12773329 Get It

Abstract Idiopathic interstitial pneumonias are a diverse group of lung diseases with varied prognoses. We hypothesized that changes in physiologic and radiographic parameters would predict survival. We retrospectively examined 80 patients with usual interstitial pneumonia and 29 patients with nonspecific interstitial pneumonia. Baseline characteristics were examined together with 6-month change in forced vital capacity, diffusing capacity for carbon monoxide, and ground glass infiltrate and fibrosis on high resolution computed tomography. Patients with usual interstitial pneumonia were more likely to have a statistically significant or marginally significant decline in lung volume, diffusing capacity for carbon monoxide, and an increase in ground glass infiltrates (p ⩽ 0.08) compared with patients with nonspecific interstitial pneumonia. For patients with usual interstitial pneumonia, change in forced vital capacity was the best physiologic predictor of mortality (p = 0.05). In a multivariate Cox proportional hazards model controlling for histopathologic diagnosis, gender, smoking history, baseline forced vital capacity, and 6-month change in forced vital capacity, a decrease in forced vital capacity remained an independent risk factor for mortality (decrease &gt; 10%; hazard ratio 2.47; 95% confidence interval 1.29, 4.73; p = 0.006). We conclude that a 6-month change in forced vital capacity gives additional prognostic information to baseline features for patients with idiopathic interstitial pneumonia.
Fibroblastic Foci in Usual Interstitial Pneumonia: Idiopathic versus Collagen Vascular Disease
Flaherty, Kevin R. , Colby, Thomas V. , Toews, Galen B., Mumford, Jeanette A. , Murray, Susan , Kazerooni, Ella A. , Gross, Barry H., Lynch, Joseph P., Travis, William D. , Thannickal, Victor J. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 8, 2003 | Volume: 167 | Issue: 10 | Pages: 1410-1415

10.1164/rccm.200204-373oc | PMID 12615630 Get It

Abstract A histologic feature of usual interstitial pneumonia is the presence of fibroblastic foci. As some patients with usual interstitial pneumonia and an underlying collagen vascular disease have a better prognosis, we hypothesized that they would have fewer fibroblastic foci. Pathologists reviewed surgical lung biopsies from 108 patients with usual interstitial pneumonia (nine with collagen vascular disease) and assigned a score (absent 0, mild 1, moderate 2, and marked 3) for fibroblastic foci. Patients with idiopathic usual interstitial pneumonia had a higher median profusion of fibroblastic foci (1.75 vs. 1.0, p = 0.003). Baseline characteristics were similar, although patients with a collagen vascular disease were younger, had a shorter duration of symptoms, and had a higher percentage of predicted total lung capacity. Profusion of fibroblastic foci was the most discriminative feature for separating idiopathic from collagen vascular disease–associated usual interstitial pneumonia (odds ratio 8.31; 95% confidence interval, 1.98, 59.42; p = 0.002 for a one-unit increase in fibroblastic foci score). No deaths were noted in the collagen vascular disease–associated usual interstitial pneumonia group; 52 deaths occurred in the idiopathic usual interstitial pneumonia group (log rank; p = 0.005). We conclude that patients with collagen vascular disease–associated usual interstitial pneumonia have fewer fibroblastic foci and improved survival.
Future Research Directions in Acute Lung Injury: Summary of a National Heart, Lung, and Blood Institute Working Group
Matthay, Michael A. , Esmon, Charles, Bhattacharya, Jahar , Floros, Joanna, Gimbrone, Michael A., Hubmayr, Rolf D., Matalon, Sadis , Munford, Robert S., Parsons, Polly E., Slutsky, Arthur S. , Tracey, Kevin J. , Ward, Peter A. , Gail, Dorothy B., Harabin, Andrea L., Zimmerman, Guy A. , Esmon, Charles T., Coller, Barry S. , Doerschuk, Claire M. , Hoffman, Eric P. , Leppert, Mark

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 27, 2003 | Volume: 167 | Issue: 7 | Pages: 1027-1035

10.1164/rccm.200208-966ws | PMID 12663342 Get It

Abstract Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), are syndromes of acute respiratory failure that result from acute pulmonary edema and inflammation. The development of ALI/ARDS is associated with several clinical disorders including direct pulmonary injury from pneumonia and aspiration as well as indirect pulmonary injury from trauma, sepsis, and other disorders such as acute pancreatitis and drug overdose. Although mortality from ALI/ARDS has decreased in the last decade, it remains high. Despite two major advances in treatment, low VT ventilation for ALI/ARDS and activated protein C for severe sepsis (the leading cause of ALI/ARDS), additional research is needed to develop specific treatments and improve understanding of the pathogenesis of these syndromes. The NHLBI convened a working group to develop specific recommendations for future ALI/ARDS research. Improved understanding of disease heterogeneity through use of evolving biologic, genomic, and genetic approaches should provide major new insights into pathogenesis of ALI. Cellular and molecular methods combined with animal and clinical studies should lead to further progress in the detection and treatment of this complex disease.
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial
Holmes, David R. , Lablanche, J M, Grip, Lars, Serruys, P. W., Fitzgerald, Peter J., Goldberg, Sheldon, Brinker, Jeffrey, Zeiher, Andreas M. , Shapiro, Leonard M., Willerson, James T., Davis, Barry R. , Ferguson, James J., Popma, Jeffrey J. , King, Spencer B., Tcheng, James E. , Chan, Robert , Granett, Jeffrey R., Poland, Marcia, Savage, Michael P. , Fischman, David L. , Lincoff, A. Michael

Mayo Clinic

Circulation | September 3, 2002 | Volume: 106 | Issue: 10 | Pages: 1243-1250

10.1161/01.cir.0000028335.31300.da | PMID 12208800 Get It

Background— Restenosis after percutaneous coronary intervention (PCI) is a major problem affecting 15% to 30% of patients after stent placement. No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic restenosis after PCI. Methods and Results— In this double-blind, randomized, placebo-controlled trial of tranilast (300 and 450 mg BID for 1 or 3 months), 11 484 patients were enrolled. Enrollment and drug were initiated within 4 hours after successful PCI of at least 1 vessel. The primary end point was the first occurrence of death, myocardial infarction, or ischemia-driven target vessel revascularization within 9 months and was 15.8% in the placebo group and 15.5% to 16.1% in the tranilast groups ( P =0.77 to 0.81). Myocardial infarction was the only component of major adverse cardiovascular events to show some evidence of a reduction with tranilast (450 mg BID for 3 months): 1.1% versus 1.8% with placebo ( P =0.061 for intent-to-treat population). The primary reason for not completing treatment was ≥1 hepatic laboratory test abnormality (11.4% versus 0.2% with placebo, P <0.01). In the angiographic substudy composed of 2018 patients, minimal lumen diameter (MLD) was measured by quantitative coronary angiography. At follow-up, MLD was 1.76±0.77 mm in the placebo group, which was not different from MLD in the tranilast groups (1.72 to 1.78±0.76 to 80 mm, P =0.49 to 0.89). In a subset of these patients (n=1107), intravascular ultrasound was performed at follow-up. Plaque volume was not different between the placebo and tranilast groups (39.3 versus 37.5 to 46.1 mm 3 , respectively; P =0.16 to 0.72). Conclusions— Tranilast does not improve the quantitative measures of restenosis (angiographic and intravascular ultrasound) or its clinical sequelae.